The BETi showed differential efficacy in inducing cell death in five DLBCL cell lines with different endogenous BCL2A1 expression levels, with the BET degraders overall being more potent in inducing cell death than the acetyl-lysine inhibitors. This evidence concerns the gene BCL2A1 and diffuse large B-cell lymphoma.